Abstract

Cancer cell migration requires that cells respond and adapt to their surroundings. In the absence of extracellular matrix cues, cancer cells will undergo a mesenchymal to ameboid transition, whereas a highly confining space will trigger a switch to “leader bleb-based” migration. To identify oncogenic signaling pathways mediating these transitions, we undertook a targeted screen using clinically useful inhibitors. Elevated Src activity was found to change actin and focal adhesion dynamics, whereas inhibiting Src triggered focal adhesion disassembly and blebbing. On non-adherent substrates and in collagen matrices, amoeboid-like, blebbing cells having high Src activity formed protrusions of the plasma membrane. To evaluate the role of Src in confined cells, we use a novel approach that places cells under a slab of polydimethylsiloxane (PDMS), which is held at a defined height. Using this method, we find that leader bleb-based migration is resistant to Src inhibition. High Src activity was found to markedly change the architecture of cortical actomyosin, reduce cell mechanical properties, and the percentage of cells that undergo leader bleb-based migration. Thus, Src is a signal transducer that can potently influence transitions between migration modes with implications for the rational development of metastasis inhibitors.

Highlights

  • During cancer metastasis, migrating cells encounter diverse environments

  • To identify oncogenic signaling pathways that may influence mesenchymal-to-amoeboid transition (MAT), we undertook a targeted screen using, with the exception of U0126, small molecule kinase inhibitors currently FDA-approved or in clinical trials for the treatment of various cancers. This screen revealed that the Src inhibitor, Dasatinib, currently prescribed for the treatment of chronic myeloid leukemia (CML), could trigger rapid de-adhesion of human BRAF V600E mutant melanoma A375 cells from fibronectin-coated glass, as monitored by the enhanced green fluorescent protein (EGFP)-tagged focal adhesion marker paxillin (Figs. 1a, b and Supplementary Movies 1, 2)

  • The present study was aimed at identifying signaling pathways that may dictate the migration strategy used by BRAF V600E-mutated human melanoma cells

Read more

Summary

Introduction

During cancer metastasis, migrating cells encounter diverse environments. Because of this, metastasis requires that cells be inherently flexible. Once engaged with the ECM, activated integrins will recruit a host of proteins, including paxillin, focal adhesion kinase (FAK), Src, talin, vinculin, α-actinin, and many others to form a “focal. The tyrosine kinases FAK and Src form a signaling complex that begins with the auto-phosphorylation of FAKY397. This site is recognized by the SH2 domain of Src, and FAK is subsequently phosphorylated on two additional sites, Y576 and Y577, leading to full activation of FAK. Because FAK and Src are important for determining focal adhesion dynamics, and, cancer cell proliferation, survival, and migration, they are the targets of some of the newer anticancer drugs (i.e., Dasatinib and Defactinib). For the treatment of solid tumors, these drugs and others have been met with limited success [10]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call